Femasys (FEMY) announced a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. “This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care,” said Kathy Lee-Sepsick, Chief Executive Officer of Femasys. “With Refuah’s trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed by providing a more accessible, cost-effective, and patient-centered starting point for fertility treatment.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys files to sell 68.42M shares of common stock for holders
- Femasys Launches At-the-Market Common Stock Offering
- Femasys Gains FDA Clearance for FemVue Diagnostic Device
- Femasys secures U.S. FDA clearance for FemVue Controlled device
- PharmaCyte sells Femasys stake, sees cash position rising to $20M